AT&T’s Core Cellphone Business Drives Growth in Q3

1 Mins read

AT&T’s core cellphone business experienced steady growth in the third quarter, resulting in increased revenue and prompting the company to raise its full-year outlook for free cash flow. Although AT&T shares have declined by about 22% this year, they rose nearly 4% to $14.85 in premarket trading.

Impact of Restructuring

AT&T’s quarterly earnings were impacted by severance and restructuring charges due to the ongoing consolidation of offices, which is part of the company’s cost-cutting plan.

Earnings Highlights

  • Revenue: Third-quarter revenue increased 1% to $30.4 billion, exceeding the $30.21 billion expected by Wall Street analysts (according to FactSet).
  • Adjusted Profit: Adjusted earnings amounted to 64 cents per share, surpassing the estimated 62 cents per share.
  • Free Cash Flow: AT&T achieved a third-quarter free cash flow of $5.2 billion, up from $3.8 billion in the previous year.
  • Positive Outlook: AT&T is confident in achieving approximately $16.5 billion in free cash flow for the year, surpassing its previous outlook of at least $16 billion.

AT&T’s positive performance in the third quarter sets an optimistic tone for the telecommunications industry. Verizon and T-Mobile are set to announce their own updates next week.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

4 + 4 =